Smithfield Trust Co Has $45,000 Stock Position in Hologic, Inc. (NASDAQ:HOLX)

Smithfield Trust Co lifted its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 160.0% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 650 shares of the medical equipment provider’s stock after buying an additional 400 shares during the period. Smithfield Trust Co’s holdings in Hologic were worth $45,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of HOLX. Swedbank AB raised its holdings in shares of Hologic by 18.8% during the 3rd quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider’s stock worth $157,788,000 after buying an additional 306,562 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in shares of Hologic by 55.1% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 7,449 shares of the medical equipment provider’s stock worth $607,000 after buying an additional 2,645 shares in the last quarter. Stephens Inc. AR raised its holdings in shares of Hologic by 50.8% during the 3rd quarter. Stephens Inc. AR now owns 6,445 shares of the medical equipment provider’s stock worth $525,000 after buying an additional 2,172 shares in the last quarter. Farther Finance Advisors LLC raised its holdings in shares of Hologic by 27.4% during the 3rd quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical equipment provider’s stock worth $164,000 after buying an additional 434 shares in the last quarter. Finally, Van ECK Associates Corp acquired a new position in shares of Hologic during the 3rd quarter worth $725,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Stock Down 0.4 %

Shares of NASDAQ:HOLX opened at $62.08 on Thursday. The business’s 50 day simple moving average is $68.77 and its two-hundred day simple moving average is $75.64. The firm has a market cap of $13.93 billion, a P/E ratio of 19.58, a PEG ratio of 2.14 and a beta of 0.97. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. Hologic, Inc. has a 52-week low of $61.70 and a 52-week high of $84.67.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, research analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have issued reports on HOLX. Leerink Partnrs cut Hologic from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 6th. Jefferies Financial Group began coverage on Hologic in a report on Tuesday, December 10th. They issued a “hold” rating and a $85.00 target price for the company. StockNews.com raised Hologic from a “hold” rating to a “buy” rating in a report on Thursday, November 14th. Needham & Company LLC cut Hologic from a “buy” rating to a “hold” rating and set a $90.00 target price for the company. in a report on Monday, February 3rd. Finally, Wolfe Research assumed coverage on Hologic in a research note on Friday, December 13th. They issued a “peer perform” rating for the company. Eleven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $84.62.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.